





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigniia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/956,924	09/21/2001	Hideaki Yagi	Q66252	2470
75	590 07/22/2003			
SUGHRUE MION ZINN MACPEAK & SEAS, PLLC			EXAMINER	
2100 Pennsylva Washington, Do	ania Avenue, NW C 20037-3213		RADEMACHER, MARK A	
			ART UNIT	PAPER NUMBER
			3761	*

DATE MAILED: 07/22/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	1	Application No.	Applicant(s)			
	Office Action Commons	09/956,924	YAGI ET AL.			
Office Action Summary		Examiner	Art Unit			
		Mark Rademacher	3761			
 Period f	The MAILING DATE of this communication app Reply	ears on the cover sheet with the co	orrespondence address			
THE M - Extens after S - If the p - If NO p - Failure - Any re	RTENED STATUTORY PERIOD FOR REPLY ALLING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.13 IX (6) MONTHS from the mailing date of this communication. eriod for reply specified above is less than thirty (30) days, a reply eriod for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, by received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	ely filed will be considered timely. he mailing date of this communication. 0 (35 U.S.C. § 133).			
1)	Responsive to communication(s) filed on	<u> </u>				
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.				
→ 3)□ Dispositio	Since this application is in condition for allowa closed in accordance with the practice under to of Claims					
4)🛛 (Claim(s) $1-12$ is/are pending in the application					
. 4	a) Of the above claim(s) is/are withdraw	vn from consideration.				
5) 🗌 (Claim(s) is/are allowed.	•	.*			
6)⊠ Claim(s) <u>1-12</u> is/are rejected.						
7)⊠ ˙ (Claim(s) <u>1-12</u> is/are objected to.					
•	Claim(s) are subject to restriction and/or	r election requirement.				
Application						
•	he specification is objected to by the Examine					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.						
12\□ T	he oath or declaration is objected to by the Ex	,				
.—						
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
	All b) Some * c) None of:	i priority under 55 5.5.5. 3 1 15(a)) (d) 51 (1).			
, _	1.⊠ Certified copies of the priority documents	s have been received				
	2. Certified copies of the priority documents		on No			
;	Copies of the certified copies of the prior application from the International Buse the attached detailed Office action for a list	rity documents have been receive reau (PCT Rule 17.2(a)).	d in this National Stage			
	cknowledgment is made of a claim for domesti	·				
a)	☐ The translation of the foreign language procknowledgment is made of a claim for domesti	visional application has been rec	eived.			
Attachment	•					
1) Notice	of References Cited (PTO-892)	4) Interview Summary	(PTO-413) Paper No(s)			

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5.

6) Other:

5) Notice of Informal Patent Application (PTO-152)

Art Unit: 3761

DETAILED ACTION

Priority

1. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Specification

- 2. The use of the trademark SIROOCO® has been noted in this application. It should be capitalized wherever it appears and be accompanied by the generic terminology.
- 3. Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner that might adversely affect their validity as trademarks.
- The disclosure is objected to because the applicant has used sixth paragraph, means-plusfunction language to define features of the applicants' invention. Accordingly, the examiner
 requires the applicants to amend the specification pursuant to 37 CFR 1.75(d) and MPEP
 608.01(o) to explicitly state, with reference to the terms and phrases of the claim element, what
 structure, materials, and acts perform the function recited in the claim element. Please note that
 the MPEP states, "Even if the disclosure implicitly sets forth the structure, materials, or acts
 corresponding to the means-(or step-) plus-function claim element in compliance with 35 U.S.C.
 112, first and second paragraphs, the PTO may still require the applicants to amend the
 specification pursuant to 37 CFR 1.75(d) and MPEP 608.01(o)...". (Also see MPEP 2181 (Rev.
 1, Feb.2000)).

Appropriate correction is required.

Art Unit: 3761

Claim Objections

Page 3

- 5. Claims 2, 3, 9 and 10 objected to for the following reasons. In claims 2 and 9 the applicants recites "a continuous base flow rate when a breath-synchronized operation is not performed, which represents a flow rate at which the oxygen enriching apparatus can supply the oxygen-enriched gas continuously." The nature of a flow rate that "represents" another flow rate is not clear form the specification, the claims or the prior art.
- 6. In order to increase the clarity of the claims the examiner suggests that the applicants correct the above clauses to read "a continuous base flow rate that is the flow rate at which the oxygen apparatus can supply oxygen-enriched gas continuously", or "which third flow rate that is the flow rate at which the oxygen enriching apparatus can supply the oxygen-enriched gas continuously".
- 7. In addition, claims 1-5 are objected to because the applicants has evoked sixth paragraph, means-plus-function language to define features of the applicants' invention. Therefore the examiner objects to the claims for the reasons set forth above in the objection to the specification.

Appropriate correction is required. The applicants are invited to review the claims and make like corrections and clarifications where necessary.

Claim Rejections - 35 USC § 102

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 3761

9. Claims 1-5, 10-12 are rejected under 35 U.S.C. 102(b) as being anticipated by US patent no. 4,706,664 to *Snook et al.*

- 10. Snook et al disclose a supplemental oxygen apparatus that includes means for supplying oxygen-enriched gas either intermittently in conjunction with a patient's breathing cycle or continuously that includes all of the features recited in claims 1, 3-5, 11 and 12.
- 11. For example, in the embodiment described in FIG 19 means (the same or equivalent of those disclosed by the applicant) for supplying oxygen enriched gas at a first flow rate equal to or less than the rate at which the apparatus can supply the oxygen-enriched gas continuously include demand solenoid valves (22 and 26). See, e.g., column 6, lines 39-51 and column 9, lines 44-52.
- Means for supplying the oxygen enriched gas at a second flow rate greater than the continuous base flow rate during an inhalation period having a length 25 to 40% of a user's breathing cycle during a breath-synchronized operation is performed include a pressure sensor (102), control circuit (1200) and valves (22 and 26). See, e.g., column 6, lines 39-65 and column 13, lines 7-30.
- 13. With respect to claim 2, *Snook et al* disclose that the means that comprise control valves (20, 22) that establish a continuous flow mode of operation. See column 6, lines 39-51. *Snook et al* further disclose that the base flow rate may be set to as low as one liter per minute. See, e.g., the paragraph bridging columns 12 and 13.
- 14. With respect to claims 3-5, *Snook et al* disclose means for detecting the state of inhalation or exhalation based on the output of the sensor including the control circuitry (1200) and valves,

Art Unit: 3761

which determines the timing of the supply of oxygen over one or a number of inhalations or exhalations. See, e.g., column 12, lines 22-40.

- 15. With respect to claim 10, *Snook et al* also disclose a switch as recited in the form of selector 73. See, e.g., column 11, lines 33-38.
- 16. With respect to claims 11 and 12 *Snook et al* discloses a controller and recording medium as recited in the form of controller 1200 and its ROM for example.

Claim Rejections - 35 USC § 103

- 17. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 18. Claims 6-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over US patent no. 4,706,664 to *Snook et al* in view of in view of US patent no. 6,237,594 to *Davenport*.
- 19. Snook et al disclose all of the features recited in claim 17 except one or more tanks in series in the oxygen-enriched-gas supply passage.
- 20. However, the use of one or more tanks in an oxygen supply passage was known at the time of invention. For example, *Davenport* discloses an oxygen supply device wherein a number of tanks (i.e., boluses 46 and 50) are used to allow the device to deliver a broad range of flow to the patient without negatively impacting the performance of the valves and sensors. A check valve (62) is provided between the boluses. See column 5, lines 60-68.
- 21. Accordingly, it would have been obvious to one with ordinary skill in the art to modify the Snook et al device to include additional tanks in the gas supply line as taught by Davenport in

Art Unit: 3761

order to allow the apparatus to deliver gas over a wide range of flow rates without negatively impacting the performance of the valves and sensors.

22. Regarding the size of the tanks recited in claim 9, although the size of the tanks/boluses is not expressly disclosed, it is well known that the greater the size of the buffer tanks, the greater the efficiency in delivering gas to a patient over a wide range of flow rates. See, e.g., the discussion of Table 4 of US patent no. 4,681,099 to *Sato et al.* Accordingly, because the applicants does not disclose that a tank sized at 500ml or more solves a problem or provides an advantage not addressed in the prior art, it would have been an obvious design choice to provide tanks having at least 500 ml capacity in order to efficiently provide the range of desired flow rates.

Additional Pertinent Prior Art

23. The following prior art is pertinent to the applicant's disclosure: US patent nos. 6,378,520 to *Davenport*, 5,626,131 to *Chua et al*, 5,137,017 to *Salter*, and 4,686,974 to *Sato et al*.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Rademacher whose telephone number is (703) 305-0842. The examiner can normally be reached on Monday through Friday, 9:30am - 6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Weilun Lo can be reached on (703) 308-1957. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9302 for regular communications and (703) 872-9303 for After Final communications.

Art Unit: 3761

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0858.

MAR June 26, 2003

GLENN K. DAWSON PRIMARY EXAMINER